Heart attack, medically termed as Acute Myocardial Infarction is a potentially fatal condition resulting from total obstruction of one of the coronary artery transporting blood to the heart. Nearly 50% of such patients would die in the initial hour of the commencement of chest pain. Hence, time is critical. In this case, time is not money but time is muscle. Notable advancements in heart attack management have majorly lowered the death rate and brought about a whirlwind of positive change.
Hyper acute emergency – crisis management strategies
Reperfusion of the heart muscle done by opening the obstructed artery by either Primary angioplasty or by clot-absolving medicine is the decisive treatment that is successfully employed.
Elaxim –Tenecteplase justly earns the accolades for being a life-giving drug. Its clot-busting properties have the potential to terminate a heart attack. Injections could be administered IV bolus either at the patient’s home, in the ambulance or Intensive Care Cardiac Unit.
Administering these injections on time could make a major distinction between being alive and fatality. In the global setting noted since 2000, elaxim is the swiftest delivery clot buster. If the injection is promptly delivered within six hours of the commencement of chest discomfort and pain, it could cause a positive change in the end result of heart attack cases. It releases the blockage in the artery in nearly 85% of heart attack cases and normalised TIMI III flow is attained. Prompt treatment guarantees favourable results with negligible complications.
Elaxim has been proven to have better efficiency as compared to earlier clot-busting medicines such as streptokinase and urokinase, as it could be administered I.V.bolus, is clot or fibrin specific, is non-allergic and leads to lesser extent of bleeding.
PAMI or Primary Angiography is deemed the gold standard for treating heart attacks. However, the procedure must be conducted in a Cath Lab in a hospital within a time span of ninety minutes from the commencement of chest pain. This critical time factor is quiet difficult to achieve. Statistics reveal that merely 4.2% patients in the United States and six percent in Europe are lucky enough to receive the treatment within the ninety minute time limit.
In several countries, even this is tricky and rather unfeasible to attain. This reveals that the so-professed gold-standard is a mirage for many, though PAMI does have its own standing. PAMI has to be carried out by proficient, adroit surgeons with state-of-the-art facilities, high volume centre with door to balloon period not crossing over ninety minutes.